VarmX
Leiden, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $30M
Overview
Developing a specific reversal agent for Factor Xa inhibitor anticoagulants to control dangerous bleeding events.
Hematology
Technology Platform
A protein engineering platform to create biospecific reversal agents that are activated only in the presence of a target drug, like an anticoagulant.
Funding History
1Total raised:$30M
Series B$30M
Opportunities
A large and growing population on Factor Xa inhibitors creates a steady demand for safe and effective emergency reversal options.
Risk Factors
Clinical and commercial risk of entering a market with an already-approved competitor, requiring clear differentiation to gain adoption.
Competitive Landscape
Directly competes with AstraZeneca's Andexxa, the only approved specific reversal agent for Factor Xa inhibitors, in a niche but critical hospital market.